Fc receptor

Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Pharmaceutical, Health, GC, Lightspeed Venture Partners, IND, Seismology, Patient, Investment, Machine learning, GV, Series, Venture round, PD-1, IMPACT, MBA, Doctor of Philosophy, Bidirectional, DCB, Growth, Fc receptor, Polaris Partners, Drug development, Pharmaceutical industry

Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.

Key Points: 
  • Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.
  • In addition, the Series B will enable the continued growth of the company’s pipeline in both the IgSc and DcB product areas, beyond the lead programs.
  • This progress resulted from Seismic’s integration of leading-edge machine learning into drug development in a specific area – biologics for immunology – powered by a diverse team of drug developers and machine learning innovators.
  • “This financing enables us to continue our momentum and advance both of our exciting lead programs into the clinic.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda

Retrieved on: 
Tuesday, December 12, 2023
Immune system, Electromyography, Disease, Prednisone, Neurological disorder, Pain management, Fatigue, Rituximab, Patient, Gesellschaft mit beschränkter Haftung, EU4, CIDP, Azathioprine, Atrophy, Antibody, Sensation, MRI, Fc receptor, IVIG, Clumsy, Facial muscles, LAS, Neuropathic pain, Diagnosis, Inflammation, Sympathetic nervous system, Pharmaceutical industry, Takeda, Octapharma

LAS VEGAS, Dec. 12, 2023 /PRNewswire/ -- DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report includes a comprehensive understanding of current treatment practices, chronic inflammatory demyelinating polyneuropathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight estimates, CIDP in the US showed that males account for the highest number of cases as compared to females in 2022.
  • The promising chronic inflammatory demyelinating polyneuropathy therapies in the pipeline include Panzyga, Efgartigimod, Batoclimab, SAR445088, Nipocalimab, and others.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes progressive weakness and reduced sensation in the arms and legs.
  • CIDP shows itself through symmetrical weakness in the hands, feet, hips, and shoulders, gradually worsening over a minimum of two months.

Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis

Retrieved on: 
Tuesday, June 27, 2023
Communication, US Food Sovereignty Alliance, Disease, MuSK protein, Doctor of Philosophy, Thymectomy, GMG, Efgartigimod alfa, Fc receptor, Antibody, Immunoglobulin G, Enzyme inhibitor, Ravulizumab, UCB, Patient, MG, Muscular Dystrophy Association, Acetylcholine receptor, Neonatal Fc receptor, MDA, FDA, Pharmaceutical industry, Vaccine, Eculizumab

New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Key Points: 
  • New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
  • RYSTIGGO is the only FDA-approved treatment in adults for both anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG, and will be administered as an injection for subcutaneous infusion.
  • Although treatment with RYSTIGGO will not cure gMG, it could lead to functional improvements that improve the daily life of individuals with gMG.
  • “Rystiggo is a welcome addition to the targeted therapeutic options available for the treatment of generalized myasthenia gravis,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Retrieved on: 
Tuesday, June 27, 2023
GTA MyCar, Neurotransmission, University, MuSK protein, Lancet Neurology, GMG, Pathology, Fc receptor, Acetylcholine, Disease management, Immunoglobulin G, There, Information, U.S. FDA, UCB, Protein, Patient, University of Toronto, Division, Brussels Stock Exchange, Autoimmune disease, NMJ, University Health Network, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, The Lancet, Food, Safety, Disease, Pharmaceutical industry, Vaccine, Neurology

"There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.

Key Points: 
  • "There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.
  • RYSTIGGO ® is a new treatment option, targeting one of the mechanisms of disease to provide symptom improvement in patient-and physician reported outcomes at day 43."
  • The approval of RYSTIGGO® means doctors have an additional approved treatment option for their gMG patients who have not yet found a treatment that meets their needs."
  • RYSTIGGO® is also currently under review by the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of adults with gMG.

Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment

Retrieved on: 
Monday, October 24, 2022
NOG, Therapy, Neoplasm, Autoimmune disease, Animal, Tissue, Taconic Biosciences, Immune system, Drug discovery, FC, GLOBE, Monoclonal antibody, Solution, Fc receptor, Vaccine, Taconic

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.

Key Points: 
  • RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.
  • Murine FcRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery.
  • Taconics FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.
  • The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse.

Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Allergy, Risk, American Academy, Company, Swelling, Research, Patient, Investment, Goal, NASDAQ, American Academy of Allergy, Asthma, and Immunology, Review, Therapy, Hereditary angioedema, Asthma, Half-life, Abdomen, COVID-19, D, FDA, Pharmacy, IND, Facebook, Bradykinin, Plasma, Time, Conference, Plasma kallikrein, Forward-looking statement, Instagram, IPR, Safety, Genetic disorder, LinkedIn, Twitter, Face, Acquisition, SEC, Drug discovery, Advanced Materials and Processes Research Institute, Annual report, Investigational New Drug, Fc receptor, Pharmaceutical industry, Vaccine, Online gambling, Fine chemical, Internet service provider, HAE

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • We expect initial results by year end, said Jill C. Milne, Ph.D., Chief Executive Officer of Astria.
  • The goal for STAR-0215 is to provide the most patient-friendly preventative treatment option for people living with HAE.
  • Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling.

Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference

Retrieved on: 
Thursday, April 21, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Fc receptor, Investigational New Drug, IND, File, COVID-19, Pharmacy, Twitter, HAE, Annual report, Hereditary angioedema, Translational medicine, Drug discovery, Patient, Pharmacology, LinkedIn, Conference, Plasma kallikrein, Review, Allergy, Company, SEC, Forward-looking statement, Instagram, Facebook, FDA, Risk, Therapy, Time, Pharmaceutical industry

The oral presentation will be presented in-person by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics, on Wednesday, April 27th at 3:00pm ET.

Key Points: 
  • The oral presentation will be presented in-person by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics, on Wednesday, April 27th at 3:00pm ET.
  • The companys goal is to provide the most patient-friendly preventative treatment option for HAE.
  • Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases.
  • Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Retrieved on: 
Tuesday, March 22, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Risk, Urinary tract infection, Degenerative disease, Vaccine, SEC, Urination, Immunoglobulin G, Sore throat, Twitter, Phlegm, Tell, Fatigue, IIP, Immunization, FC, Trial of the century, Fc receptor, Halozyme, Pain, View, Immune system, Steroid, U.S. Securities and Exchange Commission, Swelling, Wheeze, Cough, Acetylcholine receptor, Annual report, Facial expression, Rash, Neuromuscular Disorders, MG, SC, Muscle, Back pain, Respiratory tract infection, Instagram, Patient, Form 20-F, Infection, Speech, Antibody, Company, LinkedIn, Headache, Neonatal Fc receptor, Skin, Fever, Food, Administration, Communication, Time-invariant system, Safety, Vitamin, Chest pain, US Foods, Chills, GMG, Nature, Pharmaceutical industry, Dietary supplement

In a clinical study, the most common infections were urinary tract and respiratory tract infections.

Key Points: 
  • In a clinical study, the most common infections were urinary tract and respiratory tract infections.
  • More patients on VYVGART vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts.
  • Your health care provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART.
  • The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

Spleen Tyrosine Kinase (SYK) Inhibitors Drug Pipeline Market Report 2022 with Insights from Genosco, Portola Pharma, GSK, FUJIFILM, TopiVert, Takeda Oncology, & Asana BioSciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Pharmaceutical, Health, Clinical Trials, News, SYK, Organic acid, Mammal, Antigen presentation, Cell, Macrophage, NK, II, SRC, Rheumatoid arthritis, Clinical trial, B cell, Fc receptor, Invertebrate, Inhibitor, Allergy, BCR, GPVI, Therapy, ZAP70, SH2, Degenerative disease, Neutrophil, Discovery, Pharmaceutical industry, Vaccine, Non-receptor tyrosine kinase

The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
  • SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells.
  • The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities.